摘要
目的:探讨高迁移率族蛋白B1(high mobility group box 1,HMGB1)及程序性细胞死亡配体1(programmed cell death ligand 1,PD-L1)在浸润性乳腺癌非特殊型中的表达情况及其与预后的关系。方法:收集257例女性浸润性乳腺癌非特殊型患者的病理及临床资料,采用免疫组织化学法检测浸润性乳腺癌非特殊型及同一患者正常乳腺组织HMGB1和PD-L1的表达情况,分析二者与临床病理参数的关系,并评价其预后价值。结果:HMGB1高表达与肿瘤体积大小、组织学分级、腋窝淋巴结转移、TNM分期以及雌激素受体有关(P<0.05)。PD-L1阳性表达与组织学分级、腋窝淋巴结转移、TNM分期、雌激素受体、孕激素受体、HER2以及分子分型有关(P<0.05)。在预后方面,HMGB1高表达和PD-L1阳性显著影响浸润性乳腺癌非特殊型患者的5年无复发生存率(P<0.05)。结论:HMGB1高表达和PD-L1阳性与浸润性乳腺癌非特殊型患者多项预后不良因素密切相关。HMGB1高表达和PD-L1阳性对浸润性乳腺癌非特殊型患者的术后复发预测具有一定的参考价值。
Objective:To investigate the expression of high mobility group box 1(HMGB1)and programmed cell death ligand 1(PD-L1)in non-special invasive breast carcinoma and their relationship with prognosis.Methods:We collected the pathological and clinical data of 257 cases of non-special invasive type of female invasive breast carcinoma.The expression of HMGB1 and PD-L1 in non-special breast carcinoma and normal breast tissue of the same patient was detected by immunohistochemistry.The relationship between HMGB1 and PD-L1 and clinicopathological parameters was analyzed,and the prognostic value was evaluated.Results:HMGB1 high expression was related to tumor size,histological grade,axillary lymph node metastasis,TNM stage and estrogens receptor(P<0.05).PD-L1 positive was related to histological grade,axillary lymph node metastasis,TNM stage,estrogen receptor,progesterone receptor,HER2 and molecular types(P<0.05).In terms of prognosis,HMGB1 high expression and PD-L1 positive significantly affected the five-year recurrence-free survival in patients with non-special invasive breast carcinoma(P<0.05).Conclusion:HMGB1 high expression and PD-L1 positive are closely related to many poor prognostic factors in non-special invasive breast carcinoma.HMGB1 high expression and PD-L1 positive may be useful in predicting the recurrence of non-special invasive breast carcinoma.
作者
华湘黔
张漾
HUA Xiangqian;ZHANG Yang(Pathology Department,The Maternal and Child Health Care Hospital of Xiangtan City,Hunan Xiangtan 411100,China;Pathology Department,Xiangtan Central Hospital,Hunan Xiangtan 411100,China)
出处
《现代肿瘤医学》
CAS
2024年第3期477-481,共5页
Journal of Modern Oncology